Existing Sunscreen Monograph Ingredients Could Fail Proposed Safety Standards
This article was originally published in The Tan Sheet
Executive Summary
FDA’s proposed safety standards for sunscreen monograph ingredients might not align with safety evidence supporting current monograph ingredients. Without a safeguard, such as a grandfather clause, these ingredients could face challenges if FDA adopts stricter standards, NDAC committee members worry.
You may also be interested in...
Sunscreen Safety Framework Is FDA’s First Step, With More Tests Needed – NDAC
NDAC members agree with FDA’s proposed standards for evaluating the safety of sunscreen OTC monograph ingredients, but suggest the agency add tests to evaluate the impact of long-term use, actual use and bioavailability in specific populations.
Sunscreen Safety Framework Is FDA’s First Step, With More Tests Needed – NDAC
NDAC members agree with FDA’s proposed standards for evaluating the safety of sunscreen OTC monograph ingredients, but suggest the agency add tests to evaluate the impact of long-term use, actual use and bioavailability in specific populations.
Flaws In TEA Process Delay Reviews, Monograph Changes – FDA
The significant time and resources necessary to amend the monograph are one reason for FDA’s slow response to time and extent applications to add ingredients to the OTC sunscreen monograph, agency officials say. Another reason may be flaws in data required in the application process.